Single-Agent Ifosfamide in Patients with Recurrent Neuroblastoma (Ensg Study 2)
- 1 January 1987
- journal article
- clinical trial
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 4 (2), 101-104
- https://doi.org/10.3109/08880018709141255
Abstract
Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide. In 2 of 10 relapsing patients, an objective response was observed. If ifosfamide is administered in a dose of 3000 mg/m2 for 2 days every 3 weeks, a response can be expected in 8% of the cases.Keywords
This publication has 1 reference indexed in Scilit:
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961